Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis

doi:10.3969/j.issn.1673-8640.2023.04.009

Abstract

Abstract:

Objective To investigate the clinical significance of glycoprotein non-metastatic melanoma protein B（GPNMB） expression in non-small cell lung cancer（NSCLC）. Methods Totally，124 patients with NSCLC were enrolled from Tangshan People's Hospital from April 2016 to April 2018，and the patients' cancer tissue and adjacent tissue（2-3 cm from the edge of tumor） samples were collected. The expression level of GPNMB in the patients' cancer and adjacent tissues was determined by immunohistochemistry. The expressions of CD44，CD206 and F4/80 in cancer tissue samples were determined，and the patients were classified into high and low immunoinfiltration groups. The clinicopathologic data of all the patients were collected，and all the patients were followed up for 4.5 to 36.0 months. Kaplan-Meier survival curve analysis and Log-rank χ² test were used to evaluate NSCLC patients' survival. Results Compared to adjacent tissues，the expression level of GPNMB in cancer tissues of NSCLC patients was up-regulated（P<0.001）. There was statistical significance in GPNMB expression among NSCLC patients with different TNM stages（P<0.001），and there was no statistical significance in GPNMB expression among NSCLC patients with different ages，sex and tissue types （P>0.05）. The proportion of GPNMB high expression in high immunoinfiltration group was higher than that in low immunoinfiltration group（P<0.001）. Kaplan-Meier survival curve analysis showed that the overall survival（OS） time and progression-free survival（PFS） time of high，medium and low GPNMB expression groups were gradually prolonged（P<0.05）. Conclusions GPNMB is highly expressed in cancer tissues of NSCLC patients，and the up-regulation of its expression level is related to the degree of tumor immunoinfiltration and poor prognosis.

Key words: Glycoprotein non-metastatic melanoma protein B, Non-small cell lung cancer, Tumor immunoinfiltration, Prognosis

CLC Number:

R446.1

SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis[J]. Laboratory Medicine, 2023, 38(4): 347-351.

Figures/Tables 4

References 21.

1.	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics,2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. DOI URL
2.	YAO K, WEI L, ZHANG J, et al. Prognostic values of GPNMB identified by mining TCGA database and STAD microenvironment[J]. Aging(Albany NY), 2020, 12(16):16238-16254.
3.	GATAA I, MEZQUITA L, ROSSONI C, et al. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy[J]. Eur J Cancer, 2021, 145:221-229. DOI PMID
4.	QUAN Y H, LIM J Y, CHOI B H, et al. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells[J]. Cancer Chemother Pharmacol, 2019, 83(3):399-410. DOI
5.	KOVALEVA O V, RASHIDOVA M A, SAMOILOVA D V, et al. CHID1 is a novel prognostic marker of non-small cell lung cancer[J]. Int J Mol Sci, 2021, 22(1):450. DOI URL
6.	LIU F, WANG X, YANG Y, et al. The suppressive effects of miR-508-5p on the odontogenic differentiation of human dental pulp stem cells by targeting glycoprotein non-metastatic melanomal protein B[J]. Stem Cell Res Ther, 2019, 10(1):35. DOI PMID
7.	REN F, ZHAO Q, LIU B, et al. Transcriptome analysis reveals GPNMB as a potential therapeutic target for gastric cancer[J]. J Cell Physiol, 2020, 235(3):2738-2752. DOI PMID
8.	CHUNG J S, RAMANI V, KOBAYASHI M, et al. DC-HIL/Gpnmb is a negative regulator of tumor response to immune checkpoint inhibitors[J]. Clin Cancer Res, 2020, 26(6):1449-1459. DOI URL
9.	MARIC G, ANNIS M G, MACDONALD P A, et al. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity[J]. Oncogene, 2019, 38(26):5294-5307. DOI PMID
10.	FENG X, ZHANG L, KE S, et al. High expression of GPNMB indicates an unfavorable prognosis in glioma:combination of data from the GEO and CGGA databases and validation in tissue microarray[J]. Oncol Lett, 2020, 20(3):2356-2368. DOI URL
11.	LI Y N, ZHANG L, LI X L, et al. Glycoprotein nonmetastatic B as a prognostic indicator in small cell lung cancer[J]. APMIS, 2014, 122(2):140-146. DOI URL
12.	YARDLEY D A, WEAVER R, MELISKO M E, et al. EMERGE:a randomized phase Ⅱ study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer[J]. J Clin Oncol, 2015, 33(14):1609-1619. DOI URL
13.	DOMENIGHETTI C, SUGIER P E, SREELATHA A A K, et al. Mendelian randomisation study of smoking,alcohol,and coffee drinking in relation to parkinson's disease[J]. J Parkinsons Dis, 2022, 12(1):267-282.
14.	XU S, FAN Y, LI D, et al. Glycoprotein nonmetastatic melanoma protein B accelerates tumorigenesis of cervical cancer in vitro by regulating the Wnt/β-catenin pathway[J]. Braz J Med Biol Res, 2018, 52(1):e7567. DOI URL
15.	MA R Q, TANG Z J, YE X, et al. Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer[J]. Arch Gynecol Obstet, 2018, 297(5):1235-1244. DOI
16.	WANG S S, GU Q, LIU N, et al. Aerobic exercise attenuates ectopic renal sinus adipose tissue accumulation-related renal hypoxia injury in obese mice[J]. Life Sci, 2021, 279:119106. DOI URL
17.	LEE-SAYER S S M, MAESHIMA N, DOUGAN M N, et al. Hyaluronan-binding by CD44 reduces the memory potential of activated murine CD8 T cells[J]. Eur J Immunol, 2018, 48(5):803-814. DOI URL
18.	LI W, MA H, ZHANG J, et al. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis[J]. Sci Rep, 2017, 7(1):13856. DOI PMID
19.	LEI X, LEI Y, LI J K, et al. Immune cells within the tumor microenvironment:biological functions and roles in cancer immunotherapy[J]. Cancer Lett, 2020, 470:126-133. DOI URL
20.	BOULLE G, VELUT Y, MANSUET-LUPO A, et al. Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma[J]. Eur J Cancer, 2020, 135:221-229. DOI PMID
21.	LI H, XIAO Y, WU C C, et al. High expression of GPNMB predicts poor prognosis in head and neck squamous cell carcinoma[J]. Histol Histopathol, 2019, 34(7):803-810. DOI PMID

组别	例数	性别		年龄/岁	组织分型			TNM分期
组别	例数	男/例	女/例	年龄/岁	肺腺癌/例	肺鳞癌/例	其他分型/例	Ⅰ期/例	Ⅱ期/例	Ⅲ期/例	Ⅳ期/例
低表达组	21	10	11	55.83±14.11	11	6	4	14	5	1	1
中表达组	37	19	18	50.42±16.48	21	9	7	6	15	13	3
高表达组	66	33	33	51.57±18.49	36	17	13	3	17	36	10
统计值		0.075		0.692	0.151			47.484
P值		0.963^①		0.503	0.997^①			<0.001^①

组别	例数	性别		年龄/岁	组织分型			TNM分期
组别	例数	男/例	女/例	年龄/岁	肺腺癌/例	肺鳞癌/例	其他分型/例	Ⅰ期/例	Ⅱ期/例	Ⅲ期/例	Ⅳ期/例
低表达组	21	10	11	55.83±14.11	11	6	4	14	5	1	1
中表达组	37	19	18	50.42±16.48	21	9	7	6	15	13	3
高表达组	66	33	33	51.57±18.49	36	17	13	3	17	36	10
统计值		0.075		0.692	0.151			47.484
P值		0.963^①		0.503	0.997^①			<0.001^①

[1]	ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811.
[2]	WANG Yangshuyi, YE WEI, LIN Zhihao, HUANG Yuenuo, FANG Tao, DONG Xiaoting. Construction and validation of a model for pyroptosis-related features in lung adenocarcinoma [J]. Laboratory Medicine, 2023, 38(9): 833-841.
[3]	ZHANG Han, LI Jun, LIU Xiaojiang, GUAN Yixiang. Role of serum albumin，interleukin-6 and ferritin combined determination in evaluating the functional prognosis of patients with spontaneous intracerebral hemorrhage [J]. Laboratory Medicine, 2023, 38(8): 713-718.
[4]	ZHANG Na, NIU Weihua, SUN Yuanyuan, JIA Mei. CMV and EBV co-infection affecting patient prognosis after hematopoietic stem cell transplantation [J]. Laboratory Medicine, 2023, 38(8): 760-765.
[5]	CHEN Ying, LI Wei, LIN Tao, YANG Li. Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(7): 634-639.
[6]	GUO Jie, LI Haixia, LI Xiaoyun. Correlation of preoperative RPR in peripheral blood with the prognosis of endometrial carcinoma patients [J]. Laboratory Medicine, 2023, 38(7): 675-679.
[7]	WANG Tengfei, CHEN Shan, AN Hebing, ZHOU Lei. Expressions and roles of lncRNA CRNDE and miR-384 in peripheral blood of patients with acute leukemia [J]. Laboratory Medicine, 2023, 38(7): 686-691.
[8]	YIN Ya, PAN Yuan, ZHOU Hongwei, SHEN Wei. Application progress of BNP and NT-proBNP in neonates [J]. Laboratory Medicine, 2023, 38(6): 518-523.
[9]	ZHAO Jing, WANG Pei, LU Dandan, QI Dandan, LI Xuan. Expression levels of serum miR-4443 and TRAF4 in patients with hemorrhagic stroke [J]. Laboratory Medicine, 2023, 38(5): 413-418.
[10]	YANG Zhongxin, LI Xiaoyu, CHEN Tao, CAO Wenjun. Roles of IL-8 and MMP-2 in the prognosis of non-small cell lung cancer patients after thoracoscopic segmentectomy [J]. Laboratory Medicine, 2023, 38(4): 342-346.
[11]	LIU Junshan, GUO Mingfa, SUN Jia, SHI Lihuan, LIU Wei, DUAN Yongtao. Significance of minimal residual disease dynamic monitoring in the prognosis of acute B-lymphoblastic leukemia children with positive and negative ETV6/RUNX1 fusion genes [J]. Laboratory Medicine, 2023, 38(3): 209-214.
[12]	CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256.
[13]	GU Yi, WANG Rui, DENG Jie, YANG Yijing, ZHOU Wangke, CHEN Yunuo, CHEN Xiaosong, SHEN Wei, ZHOU Jingyi. Differential analysis and prognostic diagnostic value of inflammatory biomarkers in liver transplantation in patients with severe hepatitis and cirrhosis [J]. Laboratory Medicine, 2023, 38(11): 1044-1051.
[14]	LIANG Weizhang, SHI Jianping, CHAI Lina, HAN Aizi. Relationship between serum cathepsin K and ADAMTS-7 with ventricular remodeling and prognosis in patients with chronic heart failure [J]. Laboratory Medicine, 2023, 38(10): 919-925.
[15]	ZHOU Jun, LI Liheng, ZHANG Min. Expressions of serum miR-24 and XIAP mRNA in serum of oral adenoid cystic carcinoma patients and relationship with prognosis [J]. Laboratory Medicine, 2023, 38(10): 930-935.